Haug Partners LLP
General
Cases434
Challenger50%
Patent Owner50%
NPE50%
Practice Areas
BiotechTransport., E-Comm.Mech Eng, Manuf
Top Attorneys
Elite Ratings
DCTPTABCAFC
Analytics
Lawyers
Cases
Ratings Trends
Practice Areas
Recent Dockets
Entered | Case | Description |
|---|---|---|
| 01/06/25 | MOTION to Substitute Attorney Stuart G. Gross filed by Sartorius Bioanalytical Instruments, Inc.. (Chang, Cheryl) (Filed on 1/6/2025) (Entered: 01/06/2025) | |
| 01/06/25 | MOTION to Substitute Attorney Audrey Sparschu filed by Sartorius Bioanalytical Instruments, Inc.. (Chang, Cheryl) (Filed on 1/6/2025) (Entered: 01/06/2025) | |
| 01/06/25 | MOTION to Substitute Attorney Jonathan S. Herstoff and Camille Yvette Turner filed by Sartorius Bioanalytical Instruments, Inc.. (Chang, Cheryl) (Filed on 1/6/2025) (Entered: 01/06/2025) | |
| 01/06/25 | MOTION to Substitute Attorney Travis Smith filed by Sartorius Bioanalytical Instruments, Inc.. (Chang, Cheryl) (Filed on 1/6/2025) (Entered: 01/06/2025) | |
| 01/06/25 | [Electronic filing error] re: [39] , [40] , [41] , [42] Motions to Substitute Counsel. New Counsel, Withdrawing Counsel and Party has not signed the documents. These filing will not be processed by the clerks office. Please re-file each in its entirety. (crr, COURT STAFF) (Filed on 1/6/2025) (Entered: 01/06/2025) | |
| 12/23/24 | MOTION in Limine to Exclude Expert Testimony of Dr. Suter Pursuant to Fed. R. Evid. 702 by LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA PHARMA, LLC, THE GEORGE WASHINGTON UNIVERSITY. (Attachments: # [1] Brief, # [2] Text of Proposed Order)(CHEVALIER, CHARLES) (Entered: 12/23/2024) | |
| 12/23/24 | BRIEF in Support filed by LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA PHARMA, LLC, THE GEORGE WASHINGTON UNIVERSITY re [274] MOTION in Limine to Preclude Testimony, Evidence or Argument Regarding Non-Public FDA Correspondence Regarding Giapreza Label (CHEVALIER, CHARLES)NOTICE TO COUNSEL: Counsel is advised that pursuant to Local Civil Rule 5.3(c)(2), a single, consolidated motion to seal shall be filed within 14 days following the completed briefing of the materials sought to be sealed, or within 14 days following the date on which the last of such materials was filed under temporary seal if the motion is resolved, unless otherwise directed by the Court. (Entered: 12/23/2024) | |
| 12/23/24 | MOTION in Limine to Preclude Testimony, Evidence or Argument Regarding Non-Public FDA Correspondence Regarding Giapreza Label by LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA PHARMA, LLC, THE GEORGE WASHINGTON UNIVERSITY. (Attachments: # [1] Text of Proposed Order)(CHEVALIER, CHARLES) (Entered: 12/23/2024) | |
| 12/23/24 | MOTION in Limine to Exclude Undisclosed Invalidity References and Objection to Magistrate Judge Clark's Ruling by LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA PHARMA, LLC, THE GEORGE WASHINGTON UNIVERSITY. (Attachments: # [1] Brief, # [2] Declaration of Charles H. Chevalier, Esq., # [3] Exhibit A, # [4] Text of Proposed Order)(CHEVALIER, CHARLES) (Entered: 12/23/2024) | |
| 12/23/24 | MOTION in Limine regarding Expert Testimony and Septic Shock by FRESENIUS KABI USA LLC, FRESENIUS KABI SWISSBIOSIM GMBH, GLAND PHARMA LIMITED. (Attachments: # [1] Brief, # [2] Declaration of James Richter, # [3] Text of Proposed Order)(RICHTER, JAMES) (Entered: 12/23/2024) |